Supplement Table 1.
Example of recommendations for antibiotics and antifungal drugs
Antibiotics and antifungal drugs | Recommendation examples |
---|---|
Treatment effectiveness | |
Drug selection | A patient had gram-positive bacteria isolated from throat swabs, rising CRP, and CRRT treatment. Linezolid (0.6g q12h) was recommended for with (accepted). |
Dose selection | A patient had less than 0.5 μg/ml blood concentration of voriconazole. Increasing the dose of voriconazole to 200 mg q8h was advised (accepted). |
Treatment duration | A patient achieved near-normal indicators of bacterial infections. Considering the lack of evidence supporting infections caused by Gram positive bacteria, discontinuation of daptomycin was advised (accepted). |
Adverse drug event occurring | |
Drug selection | |
Liver function | The blood concentration of voriconazole was 5.6 μg/ml for a patient whose TBL was 101.8 μmol/L. Adjustment of antifungal drugs was recommended (voriconazole ➝ micafungin 150 mg qd, accepted). |
Central nervous system | A patient developed psychiatric symptoms, which may be caused by imipenem/cilastatin. Adjustment of antibiotics was recommended (imipenem/cilastatin ➝ cefoperazone/sulbactam 2g q8h, accepted). |
Cardiovascular system | A patient with CRRT treatment developed arrhythmia and abnormal TBL, which may be caused by levofloxacin. Discontinuation of levofloxacin was recommended. |
Skin | A patient developed skin rashes over the whole body, which may be caused by drugs. Discontinuation of caspofungin, linezolid, montelukast and olanzapine was recommended (accepted). |
Urinary system | The Scr elevated to 143 μmol/L in a patient, which may be caused by teicoplanin. Discontinuation of teicoplanin was recommended. |
Dose selection | The blood concentration of vancomycin was 33.34 μg/ml in a patient with hemodialysis treatment due to renal function failure. Discontinuation of vancomycin was recommended (accepted). |
Treatment duration | The Scr was 129 μmol/L for a patient with polymyxin B treated for 2 weeks. Discontinuation of polymyxin B was recommended. |